N/A
Completed N=2,278
A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin
Source: ClinicalTrials.gov NCT00892008 ↗Enrolled (actual)
2,278
Serious AEs
0.3%
Results posted
Nov 2009
Primary outcomePrimary: Number and Severity of Adverse Events (All Causalities); Baseline to Final Visit (Week 4) — 1; 1; 3; 1 participants
Summary
This study is being conducted as a regulatory requirement post initial marketing authorization. This is primarily a safety study. This was an open label study and patients were enrolled once the decision to prescribe the medication was made by the Investigator.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number and Severity of Adverse Events (All Causalities); Baseline to Final Visit (Week 4) |
1; 1; 3; 1; 1; 1 | — |
| PRIMARY Discontinuations Due to Adverse Events |
1; 1; 5; 3; 2; 26 | — |
| SECONDARY Change From Baseline in Visual Analogue Scale (VAS) Score |
3.5; 5.1 | — |
| SECONDARY VAS Pain Score at Baseline (BL) and Second Visit |
22; 0; 0; 0; 3; 300 | — |
| SECONDARY VAS Pain Score at Baseline and Final Visit |
12; 0; 0; 13; 272; 19 | — |
| SECONDARY Physician's Clinical Global Impression (CGI) of Treatment Satisfaction at the Second and Final Visits |
209; 6; 2; 0; 0; 55 | — |
| SECONDARY Patient's Clinical Global Impression (CGI) of Treatment Satisfaction at the Second and Final Visits |
201; 11; 1; 0; 0; 47 | — |
| SECONDARY Physician's Clinical Global Impression (CGI) of Efficacy at Second and Final Visit |
217; 8; 1; 0; 0; 53 | — |
| SECONDARY Patient's Clinical Global Impression (CGI) of Efficacy at Second and Final Visit |
206; 8; 0; 0; 0; 50 | — |
| SECONDARY Physician's Clinical Global Impression (CGI) on Tolerability at Second and Final Viist |
237; 12; 0; 0; 0; 60 | — |
| SECONDARY Patient's Clinical Global Impression (CGI) of Tolerability at Second and Final Visit |
213; 14; 0; 0; 0; 51 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female, 18 years old and above diagnosed with neuropathic pain.
Exclusion Criteria
- Patients that are pregnant and lactating; and patients with known hypersensitivity to pregabalin or its related components.
Data sourced from ClinicalTrials.gov (NCT00892008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.